We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses

Rajiv Tandon, MD; Henry A. Nasrallah, MD
Arch Gen Psychiatry. 2006;63(8):935-937. doi:10.1001/archpsyc.63.8.935.
Text Size: A A A
Published online


We read with interest the impressive meta-analysis by Davis et al1 of the efficacy of second-generation antipsychotics (SGAs) published in the ARCHIVES but were concerned about its inadequate consideration of some important methodologic limitations that may have significantly detracted from the veracity of their conclusions. There are approximately 50 different antipsychotic medications available in the world; of the 20 currently available in the United States, 6 (clozapine, risperidone, olanzapine, quetiapine fumarate, ziprasidone hydrochloride, and aripiprazole) are labeled SGAs. Perhaps because of their presumed broader spectrum of efficacy and better motor adverse-effect profile, SGAs collectively constitute more than 90% of all antipsychotic prescriptions in the United States at this time. Despite the wide popularity of these medications and their rapid adoption in general clinical practice, there are limited data on how they compare with each other with regard to their overall efficacy. In an effort to address this issue, Davis et al1 performed a meta-analysis of 124 randomized controlled trials (published and unpublished) with efficacy data on 1 of 10 SGAs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, remoxipride, risperidone, sertindole, ziprasidone, and zotepine) vs a first-generation antipsychotic (FGA). Based on their analysis, they concluded that there are 2 groups of SGAs: group 1 (comprising amisulpride, clozapine, olanzapine, and risperidone) is more efficacious than FGAs and group 2 (comprising the other 6) is not differently efficacious than FGAs. Furthermore, in an additional analysis of 18 trials comparing SGAs among each other, they found no evidence for differential efficacy among amisulpride, clozapine, olanzapine, and risperidone. Finally, they found no support for the contention that the observed greater efficacy of SGAs over FGAs in part is explained by the use of high doses of a comparator FGA (>12 mg of haloperidol per day). While the exhaustive efforts of Davis et al merit praise, key methodologic limitations in their report warrant further discussion.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

7 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...